Compare NTST & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | NBTX |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | United States | France |
| Employees | N/A | 97 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 2018 |
| Metric | NTST | NBTX |
|---|---|---|
| Price | $19.86 | $37.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | $22.02 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 840.5K | 155.1K |
| Earning Date | 04-20-2026 | 03-31-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $195,006,000.00 | N/A |
| Revenue This Year | $19.03 | $58.17 |
| Revenue Next Year | $16.25 | N/A |
| P/E Ratio | $167.00 | ★ N/A |
| Revenue Growth | ★ 19.79 | N/A |
| 52 Week Low | $17.02 | $9.32 |
| 52 Week High | $22.47 | $57.14 |
| Indicator | NTST | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.15 | 44.76 |
| Support Level | $19.88 | $35.59 |
| Resistance Level | $20.82 | $41.06 |
| Average True Range (ATR) | 0.33 | 2.57 |
| MACD | -0.03 | -0.65 |
| Stochastic Oscillator | 6.10 | 20.46 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.